Cerner Corp. and development partner Mortara Instrument have joined together to introduce CareAware Waveform Management. The system displays waveforms and other physiological data from patient monitoring systems and integrates them into the electronic health record (EHR).


Cardiac imaging accounts for about one-third of the source of X-ray radiation dose for all medical imaging. Expanding use of computed tomography (CT) for cardiac evaluations, use of nuclear imaging for myocardial perfusion exams and more complex transcatheter procedures in the cath lab have all increased patient exposure in recent years. 


The spirit of collaboration to improve health with information technology came to Cleveland, Ohio, when the Integrating the Healthcare Enterprise (IHE) North American Connectathon 2015 opened in January 2015. Almost 100 organizations and 555 engineers attended this annual testing event.

Physicians who use the clinical reference tool, DynaMed from EBSCO Health, can now access the valuable, evidence-based content anywhere with the new DynaMedmobile app. The new app has been redesigned to make it easier and faster for physicians to find answers to clinical questions.


Transcatheter aortic valve replacement (TAVR) is not only a breakthough minimally invasive medical therapy, but offers a new business opportunity for hospitals that begin a program. The technology is viewed as cutting edge not only with clinicians, but also among the general public. This can be leveraged to promote the hospital as a cutting-edge facility and help attract new patients. However, creating these programs requires long-term financial, professional and equipment commitments, which may not be right for all hospitals. There are also concerns that a proliferation of TAVR centers may make programs less profitable and reduce the proficiency of any one center as patient volumes decrease if patients are spread between many competing hospitals.


Most “risk calculators” used by clinicians to gauge a patient’s chances of suffering a heart attack and guide treatment decisions appear to significantly overestimate the likelihood of a heart attack, according to results of a study by investigators at Johns Hopkins and other institutions.

Micell Technologies, Inc. announced the commercial availability of the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) in Europe. Stentys, Micell’s distribution partner in Paris, plans a controlled launch in Western Europe followed by a full commercial launch for the second half of 2015 in selected countries within Europe, Middle East, Southeast Asia and Latin America.

Subscribe Now